RecruitingNCT05907681
Prospective Observational Study on Outcome of High-precision Hypo-fractionated Radiotherapy in Metastatic Breast Cancer (PRECISE-M)
Sponsor
Samsung Medical Center
Enrollment
400 participants
Start Date
May 11, 2023
Study Type
OBSERVATIONAL
Conditions
Summary
This study is a prospective observational study on outcomes of high precision hypo-fractionated radiotherapy in breast cancer with distant metastasis.
Eligibility
Sex: FEMALEMin Age: 19 YearsMax Age: 100 Years
Plain Language Summary
Simplified for easier understanding
This is an observational study (no experimental treatment is given) tracking the real-world outcomes of metastatic breast cancer patients who are receiving high-precision radiation therapy. The aim is to better understand how this type of radiation works in patients whose cancer has spread.
**You may be eligible if...**
- You have breast cancer that has spread to other parts of the body (metastatic)
- You are receiving or planning to receive precision radiation therapy (IMRT, SBRT, or proton therapy)
- You are willing and able to follow the study protocol
**You may NOT be eligible if...**
- You are unable to follow the study protocol
Talk to your doctor to see if this trial is right for you.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05907681
Related Trials
Genomic Services Research Program
NCT025959571 location
A Synthetic Lethality-Focused Algorithm to Identify Therapeutic Options in Advanced Metastatic Breast Cancer (SYNTHESIS-Breast)
NCT070671381 location
Social and Environmental Determinants of Breast Cancer Survivorship: the Black Breast Cancer Survivor's Intervention (BBCSI)
NCT068852031 location
A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer
NCT05894239192 locations
Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors
NCT052833304 locations